within Pharmacolibrary.Drugs.ATC.V;

model V09IA08
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 2.9999999999999997e-06,
    adminDuration  = 600,
    adminMass      = 0.01 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V09IA08</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Technetium (99mTc) etarfolatide is a radiopharmaceutical agent consisting of a technetium-99m labeled folate receptor-targeting ligand. It is used for single photon emission computed tomography (SPECT) imaging to identify folate receptor positive tumors, primarily in ovarian and other cancers. The drug is not currently FDA-approved and was primarily used in clinical trials.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult cancer patients based on typical radiopharmaceutical and SPECT imaging protocols; no published clinical pharmacokinetic models available.</p><h4>References</h4><ol><li><p>Yamada, Y, et al., &amp; Omote, M (2015). Phase I clinical trial of 99mTc-etarfolatide, an imaging agent for folate receptor in healthy Japanese adults. <i>Annals of nuclear medicine</i> 29(9) 792–798. DOI:<a href=\"https://doi.org/10.1007/s12149-015-1006-2\">10.1007/s12149-015-1006-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26238440/\">https://pubmed.ncbi.nlm.nih.gov/26238440</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V09IA08;
